Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s stock price shot up 1% on Thursday . The company traded as high as $6.52 and last traded at $6.30. 1,945,327 shares were traded during trading, an increase of 476% from the average daily volume of 337,931 shares. The stock had previously closed at $6.24.
Silverback Therapeutics Stock Up 1.0%
The company has a market cap of $227.17 million, a PE ratio of -2.60 and a beta of 0.60. The business has a 50-day simple moving average of $7.41 and a 200-day simple moving average of $8.20.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Featured Articles
- Five stocks we like better than Silverback Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
